Given the role of self renewal in cancer, targeting the pathways involved in this process has emerged as a promising therapeutic strategy. Inhibitors of key signaling pathways like Wnt, Notch, and Hedgehog are currently being developed and tested in clinical trials. These therapies aim to specifically target cancer stem cells and reduce the risk of tumor recurrence.
